These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 16469003)

  • 41. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.
    Kaplan SA; Gonzalez RR; Te AE
    Eur Urol; 2007 Jun; 51(6):1717-23. PubMed ID: 17258855
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Treatment with adrenergic alpha receptor blockaders in benign prostatic hypertrophy].
    Christensen MM; Husted SE; Nørgaard JP
    Nord Med; 1988; 103(10):282-3. PubMed ID: 2462712
    [No Abstract]   [Full Text] [Related]  

  • 43. Treatment of benign prostatic hyperplasia and hypertension in elderly hypertensive patients.
    Suzuki H
    Br J Urol; 1998 Mar; 81 Suppl 1():51-5. PubMed ID: 9589018
    [No Abstract]   [Full Text] [Related]  

  • 44. Advances in the medical management of benign prostatic hyperplasia.
    Jewett MA; Klotz LH;
    CMAJ; 2007 Jun; 176(13):1850-1. PubMed ID: 17576985
    [No Abstract]   [Full Text] [Related]  

  • 45. [Using setegis (terasosine) in early postoperative period after transurethral prostate resection].
    Teodorovich OV; Zabrodina NB; Bochkarev AB
    Urologiia; 2009; (3):62-4. PubMed ID: 19673124
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Therapeutic effect of harnal and proscar in treating benign prostatic hyperplasia].
    Tang ZY; Peng KL; Ding J; Zu XB; Qi L
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Dec; 30(6):708-10. PubMed ID: 16708816
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [The effectiveness of naftopidil in patients with benign prostatic hyperplasia evaluated by QOL index].
    Nakatsu H; Naoi M; Sekiyama K; Hamano S; Suzuki N; Tanaka M; Murakami S
    Hinyokika Kiyo; 2007 Jan; 53(1):13-8. PubMed ID: 17310763
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Benign prostatic hyperplasia: medical therapy].
    Schlenker B; Gratzke C; Weidlich P; Seitz M; Reich O; Stief CG
    MMW Fortschr Med; 2007 Aug; 149(33-34):29-31; quiz 32. PubMed ID: 17912863
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Benign prostatic hyperplasia--review of treatment options.
    Oehlke KJ; Branaugh ML
    S D Med; 2009 May; 62(5):202-3. PubMed ID: 19489345
    [No Abstract]   [Full Text] [Related]  

  • 50. Alpha-blockade: monotherapy for hypertension and benign prostatic hyperplasia.
    Kaplan SA; Kaplan NM
    Urology; 1996 Oct; 48(4):541-50. PubMed ID: 8886058
    [No Abstract]   [Full Text] [Related]  

  • 51. [Correction of urination disorders caused by benign prostatic hyperplasia in cardiac surgery].
    Koraev KN
    Khirurgiia (Mosk); 2003; (1):19-21. PubMed ID: 12645203
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Polymorphisms in the alpha1A-adrenoceptor gene do not modify the short- and long-term efficacy of alpha1-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia.
    Mochtar CA; Laan W; Van Houwelingen KP; Franke B; De La Rosette JJ; Schalken JA; Kiemeney LA
    BJU Int; 2006 Apr; 97(4):852-5. PubMed ID: 16536786
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of alpha 1-adrenergic antagonist use for benign prostatic hypertrophy on outcomes in patients with heart failure.
    Dhaliwal AS; Habib G; Deswal A; Verduzco M; Souchek J; Ramasubbu K; Aguilar D; Ma TS; Jneid HM; Bolos M; Bozkurt B
    Am J Cardiol; 2009 Jul; 104(2):270-5. PubMed ID: 19576359
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo.
    Crawford ED; Wilson SS; McConnell JD; Slawin KM; Lieber MC; Smith JA; Meehan AG; Bautista OM; Noble WR; Kusek JW; Nyberg LM; Roehrborn CG;
    J Urol; 2006 Apr; 175(4):1422-6; discussion 1426-7. PubMed ID: 16516013
    [TBL] [Abstract][Full Text] [Related]  

  • 55. KMD 3213: KAD 3213, silodosin.
    Drugs R D; 2004; 5(1):50-1. PubMed ID: 14725494
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Current role of alpha-blockers in the treatment of benign prostatic hyperplasia.
    Kaplan SA
    BJU Int; 2008 Nov; 102 Suppl 2():3-7. PubMed ID: 19032603
    [No Abstract]   [Full Text] [Related]  

  • 57. Optimising the medical management of benign prostatic hyperplasia.
    Marberger M; Harkaway R; de la Rosette J
    Eur Urol; 2004 Apr; 45(4):411-9. PubMed ID: 15041103
    [No Abstract]   [Full Text] [Related]  

  • 58. Managing benign prostate disease.
    Eddy B; Anderson C
    Practitioner; 2002 Dec; 246(1641):812-5, 817-9. PubMed ID: 12489357
    [No Abstract]   [Full Text] [Related]  

  • 59. Benign prostatic hyperplasia (BPH).
    Harv Mens Health Watch; 2006 Aug; 11(1):3. PubMed ID: 17111474
    [No Abstract]   [Full Text] [Related]  

  • 60. Bunazosin. Andante, Detantol, E 1015, E 643, EA 0643.
    Drugs R D; 1999 Dec; 2(6):417-9. PubMed ID: 10763455
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.